Oral Colchicine and Low-Dose Aspirin Combination Therapy for Non-elderly, Non-severe, Early Time From Onset, Adult Outpatients with Coronavirus Disease 2019 (COVID-19) during "The Fifth Pandemic Wave" in Japan
BACKGROUND: Treatment with antiviral drugs for non-severe, early time from onset, adult outpatients with Coronavirus Disease 2019 (COVID-19) had not been established in 2021. However, some new variants of SARS-CoV-2 had caused rapid exacerbation and hospitalization among non-elderly outpatients with COVID-19, contributing to widespread crises within healthcare systems.
METHODS: From July to October 2021, we urgently assessed a therapeutic program using oral colchicine (1.0 mg loading dose, followed approximately half a day later by 0.5 mg twice daily for 5 days, and then 0.5 mg once daily for 4 days) and low-dose aspirin (100 mg once daily for 10 days), for non-elderly, non-severe, early time from onset, adult outpatients with COVID-19. To verify its effectiveness, we set loxoprofen as a control arm, and com parison of these two arms was performed. The primary outcomes were hospitalization, criticality, and death rates.
RESULTS: Thirty-eight patients (23 receiving colchicine and low-dose aspirin [CA]; 15 receiving loxoprofen [LO]) were evaluated. Hospitalization rate was lower in the CA group (1/23; 4.3%) than in the LO group (2/15; 13.3%); however, no significant difference was found between the two groups (p=0.34). No critical cases, deaths, or severe adverse events were found in either group.
CONCLUSIONS: Our CA regimen did not show superiority over LO treatment. However, our clinical experience should be recorded as part of community health care activities carried out in Kurume City against the unprece dented COVID-19 pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The Kurume medical journal - (2024) vom: 19. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inokuchi, Tetsuaki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alternative therapy |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2739/kurumemedj.MS7012003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369983165 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369983165 | ||
| 003 | DE-627 | ||
| 005 | 20240322001425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2739/kurumemedj.MS7012003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369983165 | ||
| 035 | |a (NLM)38508737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inokuchi, Tetsuaki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral Colchicine and Low-Dose Aspirin Combination Therapy for Non-elderly, Non-severe, Early Time From Onset, Adult Outpatients with Coronavirus Disease 2019 (COVID-19) during "The Fifth Pandemic Wave" in Japan |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a BACKGROUND: Treatment with antiviral drugs for non-severe, early time from onset, adult outpatients with Coronavirus Disease 2019 (COVID-19) had not been established in 2021. However, some new variants of SARS-CoV-2 had caused rapid exacerbation and hospitalization among non-elderly outpatients with COVID-19, contributing to widespread crises within healthcare systems | ||
| 520 | |a METHODS: From July to October 2021, we urgently assessed a therapeutic program using oral colchicine (1.0 mg loading dose, followed approximately half a day later by 0.5 mg twice daily for 5 days, and then 0.5 mg once daily for 4 days) and low-dose aspirin (100 mg once daily for 10 days), for non-elderly, non-severe, early time from onset, adult outpatients with COVID-19. To verify its effectiveness, we set loxoprofen as a control arm, and com parison of these two arms was performed. The primary outcomes were hospitalization, criticality, and death rates | ||
| 520 | |a RESULTS: Thirty-eight patients (23 receiving colchicine and low-dose aspirin [CA]; 15 receiving loxoprofen [LO]) were evaluated. Hospitalization rate was lower in the CA group (1/23; 4.3%) than in the LO group (2/15; 13.3%); however, no significant difference was found between the two groups (p=0.34). No critical cases, deaths, or severe adverse events were found in either group | ||
| 520 | |a CONCLUSIONS: Our CA regimen did not show superiority over LO treatment. However, our clinical experience should be recorded as part of community health care activities carried out in Kurume City against the unprece dented COVID-19 pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 (coronavirus disease 2019) | |
| 650 | 4 | |a alternative therapy | |
| 650 | 4 | |a aspirin | |
| 650 | 4 | |a colchicine | |
| 650 | 4 | |a loxoprofen | |
| 700 | 1 | |a Homma, Tomoki |e verfasserin |4 aut | |
| 700 | 1 | |a Kitasato, Yasuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Akiyama, Mayu |e verfasserin |4 aut | |
| 700 | 1 | |a Chikasue, Ayako |e verfasserin |4 aut | |
| 700 | 1 | |a Nishii, Yuuya |e verfasserin |4 aut | |
| 700 | 1 | |a Ban, Shigeki |e verfasserin |4 aut | |
| 700 | 1 | |a Adachi, Takeki |e verfasserin |4 aut | |
| 700 | 1 | |a Sonezaki, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Masuda, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kamei, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Takenaka, Miki |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Maki |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Masaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hoshino, Tomoaki |e verfasserin |4 aut | |
| 700 | 0 | |a K-COCOA (KURUME-COVID-19 THERAPEUTIC PROGRAM BY COLCHICINE AND LOW-DOSE ASPIRIN) STUDY COLLABORATORS |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Kurume medical journal |d 1961 |g (2024) vom: 19. März |w (DE-627)NLM000924725 |x 1881-2090 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2739/kurumemedj.MS7012003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 03 | ||